Lymph node metastases of melanoma: Challenges for BRAF mutation detection

Human Pathology

Volumn 46, Issue 1, 2015, Pages 113-119

  Chen, Guoli ^a,b   Dudley, Jonathan ^a,c   Tseng, Li Hui ^a,d   Smith, Kirstin ^a   Gurda, Grzegorz T ^a   Gocke, Christopher D ^a   Eshleman, James R ^a   Lin, Ming Tseh ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

BRAF; Lymph node; Melanoma; Mutant allele specific imbalance; Tumor cellularity

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CELL STRUCTURE; CHILD; FEMALE; GENE FREQUENCY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MUTANT; MUTATION; PYROSEQUENCING; QUALITY CONTROL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT; ALLELIC IMBALANCE; BIOPSY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; LYMPH NODE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SECONDARY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELIC IMBALANCE; BIOPSY; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84915737373     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.09.014     Document Type: Article

References (35)

1. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
2. G.V. Long, A.M. Menzies, and A.M. Nagrial Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 2011 1239 1246
3. A.M. Menzies, L.E. Haydu, and L. Visintin Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma Clin Cancer Res 18 2012 3242 3249
4. W.O. Greaves, S. Verma, and K.P. Patel Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma J Mol Diagn 15 2013 220 226
5. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
6. G.A. McArthur, P.B. Chapman, and C. Robert Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332
7. K.T. Flaherty, C. Robert, and P. Hersey Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
8. A. Hauschild, J.J. Grob, and L.V. Demidov Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
9. J. Dudley, L.H. Tseng, and L. Rooper Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers Arch Pathol Lab Med 2014 [in press]
10. J.C. Dudley, G.T. Gurda, and L.H. Tseng Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma Mol Diagn Ther 18 2014 409 418
11. M.T. Lin, L.H. Tseng, and R.G. Rich Δ-PCR, a simple method to detect translocations and insertion/deletion mutations J Mol Diagn 13 2011 85 92
12. G. Chen, M.T. Olson, and A. O'Neill A virtual pyrogram generator to resolve complex pyrosequencing results J Mol Diagn 14 2012 149 159
13. M.T. Olson, C. Harrington, and K. Beierl BRAF pyrosequencing analysis aided by a lookup table Am J Clin Pathol 141 2014 639 647
14. L. Eckhart, J. Bach, J. Ban, and E. Tschachler Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity Biochem Biophys Res Commun 271 2000 726 730
15. H. Viray, K. Li, and T.A. Long A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells Arch Pathol Lab Med 137 2013 1545 1549
16. A.J. Smits, J.A. Kummer, and P.C. de Bruin The estimation of tumor cell percentage for molecular testing by pathologists is not accurate Mod Pathol 27 2014 168 174
17. K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, and M. Filipits EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases Clin Cancer Res 15 2009 4554 4560
18. C.B. Han, J.T. Ma, and F. Li EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis Cancer Lett 314 2012 63 72
19. S. Magnin, E. Viel, and A. Baraquin A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers J Mol Diagn 13 2011 485 492
20. H. Halait, K. Demartin, and S. Shah Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma Diagn Mol Pathol 21 2012 1 8
21. J. Lade-Keller, K.M. Rømer, and P. Guldberg Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas J Mol Diagn 15 2013 70 80
22. G.V. Long, J.S. Wilmott, and D. Capper Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma Am J Surg Pathol 37 2013 61 65
23. R. Jewell, P. Chambers, and M. Harland Clinicopathologic features of V600E and V600K melanoma - letter Clin Cancer Res 18 2012 6792
24. A.D. Bucheit, E. Syklawer, and J.A. Jakob Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma Cancer 119 2013 3821 3829
25. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
26. W.K. Funkhouser Jr., I.M. Lubin, and F.A. Monzon Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology J Mol Diagn 14 2012 91 103
27. R.P. Tufano, G.V. Teixeira, J. Bishop, K.A. Carson, and M. Xing BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis Medicine (Baltimore) 91 2012 274 286
28. C. Li, P. Aragon Han, and K.C. Lee Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers J Clin Endocrinol Metab 98 2013 3702 3712
29. 600) mutations in melanoma patients after resection of metastatic lymph nodes Ann Surg Oncol 19 2012 4314 4321
30. M. Colombino, M. Capone, and A. Lissia BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma J Clin Oncol 30 2012 2522 2529
31. J. Soh, N. Okumura, and W.W. Lockwood Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells PLoS One 4 2009 e7464
32. D.J. Hartman, J.M. Davison, T.J. Foxwell, M.N. Nikiforova, and S.I. Chiosea Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival Int J Cancer 131 2012 1810 1817
33. C. Spittle, M.R. Ward, and K.L. Nathanson Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma J Mol Diagn 9 2007 464 471
34. H. Shi, G. Moriceau, and X. Kong Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
35. J. Villanueva, J.R. Infante, and C. Krepler Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma Cell Reprogram 4 2013 1090 1099